Literature DB >> 8122647

Four-week treatment with omeprazole increases the metabolism of caffeine.

J B Nousbaum1, F Berthou, D Carlhant, C Riche, M Robaszkiewicz, H Gouerou.   

Abstract

OBJECTIVES: It has been suggested that omeprazole is an inducer of the cytochrome P450 1A, both in vitro and in vivo. To evaluate whether omeprazole treatment might affect the activity of P450 1A2, we performed a study of caffeine metabolism, which is mainly via P450 1A.
METHODS: Thirteen subjects (one healthy volunteer and 12 patients) who were treated with omeprazole, 20 mg each morning for 4 wk, and a control group of 13 healthy volunteers, participated in the study. A test of caffeine metabolism was performed before treatment, 28 days after beginning treatment and, whenever possible, 28 days after treatment. Blood samples were analyzed for theobromine, paraxanthine, and theophylline, by high performance liquid chromatography.
RESULTS: P4501A2 activity was determined as the ratio of (paraxanthine + theobromine + theophylline)/(metabolites + caffeine) which represents the total caffeine N-oxidative demethylations; this ratio was expressed as a percentage. For patients, on day 0, the percentage of total metabolism was 34.3% +/- 8.3; on day 28, it was 42.7% +/- 10.8; the difference was statistically significant (p < 0.01). No intra-individual variation of P450 1A2 activity was observed in the control group.
CONCLUSIONS: These results demonstrate that omeprazole increases the metabolism of caffeine, especially N-1 and N-3 demethylation pathways, after 28 days of treatment with omeprazole, and suggest that omeprazole, when used for this period, is an inducer of hepatic cytochrome P4501A2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8122647

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

Review 1.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

2.  Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions.

Authors:  N Rizzo; C Padoin; S Palombo; J M Scherrmann; C Girre
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 3.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Effects of lansoprazole on pharmacokinetics and metabolism of theophylline.

Authors:  T Kokufu; N Ihara; N Sugioka; H Koyama; T Ohta; S Mori; K Nakajima
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 5.  Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Authors:  Quan Zhou; Xiao-Feng Yan; Zhong-Miao Zhang; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

6.  Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.

Authors:  R J Fontana; T M deVries; T F Woolf; M J Knapp; A S Brown; L S Kaminsky; B K Tang; N L Foster; R R Brown; P B Watkins
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 7.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.